eISSN: 2345-6558

Free Access

Journal of Parathyroid Disease 2016;4(1):1-2
An update on sclerostin and kidney

Editorial

Hamid Nasri *

1 Nickan Research Institute, Isfahan, Iran.


Hamid Nasri
Email: hamidnasri@med.mui.ac.ir


Abstract
 

Notes

Implication for health policy/practice/research/ medical education

Sclerostin is a Wnt signaling pathway antagonist which leads to a negative regulation of bone formation by inhibiting proliferation and differentiation of osteoblasts. It can be assumed that, sclerostin which is expressed in osteocytes and some chondrocytes is able to inhibit bone formation by osteoblasts. Additionally, sclerostin prevents osteoblast proliferation and differentiation enhancing their apoptosis through canonical Wnt signaling blocking. Since chronic kidney disease-metabolic bone disorder induces cardiovascular disease and mortality in chronic kidney disease patients, the association of serum sclerostin levels and the future outcome may become a crucial entity.

Please cite this paper as: Nasri H. An update on sclerostin and kidney. J Parathyr Dis. 2016;4(1):1-2.


Comments
First name  
Last name  
Email address  
Comments  
Security code



Article
PDF


Export citation
EndNote
Reference Manager
BibTeX
Medlars
Refworks

Cite by
Google Scholar

Google Scholar
Articles by Hamid Nasri
Similar articles
Related articles

PubMed
Articles by Hamid Nasri


Article Access Statistics
Viewed
PDF Downloaded
Comments

Share this article!
Creative Commons Attribution 4.0 License This work is licensed under a Creative Commons Attribution 4.0 License.
Copyright © 2016 The Author(s)
Published by Nickan Research Institute